Publication: 267

Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).

Citation:: J Thorac Oncol vol 3 (10) 1159-65

Year:: 2008
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: Received

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 631
Children:: None

Program:: OGC
Primary Committee:: Respiratory
Sec. Committees:

Pharmas:
Grants:: CA03927, CA114558-02, CA21060, CA31946, CA31983, CA33601, CA35113, CA35421, CA37447, CA41287, CA45389, CA45418, CA45564, CA45808, CA47559, CA47577, CA47642, CA74811, CA77298, CA77440

Corr. Author:
Authors:: Antonius A Miller Xiaofei F Wang Lin Gu Philip Hoffman Jamil Khatri Frank Dunphy Martin J Edelman Michael Bolger Everett E Vokes Mark R Green

Networks:

Study: CALGB-30303
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Adult, Aged, Anemia, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Darbepoetin alfa, Dose-Response Relationship, Drug, Drug Therapy, Combination, Erythropoietin, Feasibility Studies, Female, Filgrastim, Granulocyte Colony-Stimulating Factor, Hematinics, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Mesna, Middle Aged, Neoplasm Staging, Neutropenia, Polyethylene Glycols, Prognosis, Recombinant Proteins, Survival Rate, Taxoids